Infusions of donor bone marrow cells help children with inherited skin blistering

Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.The clinical trial, led by Professor John McGrath at King’s College London in collaboration with Drs Anna Martinez and Jemima Mellerio at Great Ormond Street Hospital (GOSH), recruited 10 children with recessive dystrophic epidermolysis bullosa (RDEB).

RDEB is a painful skin disease in which very minor skin injury leads to blisters and poorly healing wounds. About 1,000 people in the UK live with RDEB. The fragile skin in RDEB also scars, develops contractures and is prone to life-shortening skin cancers. There is currently no cure for RDEB.

The Phase I/II EBSTEM trial, funded by the Sohana Research Fund with donations from Goldman Sachs Gives and support from the Dystrophic Epidermolysis Bullosa Research Association, tested the safety of the treatment and also sought to establish whether it could help to reduce the severity of the disease and improve quality of life for these patients.

During the first six months of the trial, participants were given three infusions of mesenchymal stromal cells (stem cells) grown from the bone marrow of unrelated donors. Mesenchymal stem cells (MSCs) have been shown to home to wounded tissue and mediate wound healing in previous studies. Although the cells do not survive permanently, they may still deliver clinical benefits.

The children were then monitored for a year after the cell infusions. A range of monitoring tests showed no serious adverse effects in patients who received the therapy. The pain score (level of pain) reported was on average lower than before treatment, and the severity of the condition was also reported to have lessened following the infusions. Parents also reported better wound healing, less skin redness and fewer blisters.

Overall, the paper concludes that the outcomes of the trial are promising, although this is an unblinded study of participants which may introduce a positive bias in the information reported. In interviews families reported a range of benefits from having better sleep, a parent being able to return to work part-time because of reduced caring needs, and a family being able to plan their first vacation together.

However, further work is needed to better understand the mechanisms involved – for example, whether the stem cells trigger the production of a variety of growth factors and cytokines – immune system regulators - to stimulate wound healing and reduce inflammation in the skin. Further studies are also needed to confirm the efficacy of the treatment and establish the optimal dose of cells to give RDEB patients.

Dr Gabriela Petrof, lead author from St John's Institute of Dermatology at King’s College London, said: ‘We found that wound healing improved in all 10 children and the skin was less inflamed. Many of the kids also mentioned their skin was less painful and itchy, and their parents noted how much more energetic they were.’

Professor John McGrath, senior author from St John's Institute of Dermatology at King’s College London, added: ‘In 25 years of my research on RDEB, this is the only time I have seen any treatment change the nature of the condition. The outcomes are truly impressive and injecting the MSCs raised no safety concerns. At the same time, it’s important to note that this is not a cure and that the benefits wear off after about six months.’

‘Moving forward, we are now starting to introduce repeated infusions of MSCs into routine NHS clinical care. But we are also starting new clinical trials – combining cell and gene therapy to give patients with RDEB, children and adults, even better treatments as we search for a cure for this devastating inherited skin condition.

Dr Anna Martinez Principal Investigator from GOSH said: ‘Giving the cells is straight forward, but we now have to fine tune the optimal dose and interval between infusions whilst work continues on more long term therapies”.